Chiesi Acquires KalVista for $27 Per Share, Expanding Rare Disease Portfolio

Event summary

  • Chiesi Group completed its acquisition of KalVista Pharmaceuticals on June 11, 2026, for $27.00 per share in cash, representing approximately 77.8% of KalVista’s outstanding shares.
  • KalVista’s EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema (HAE) attacks, is now part of Chiesi’s Rare Diseases business unit.
  • EKTERLY is approved in the U.S., U.K., EU, Japan, and other regions, with ongoing studies for pediatric use and multiple regulatory applications under review.
  • KalVista’s common stock ceased trading on the Nasdaq Global Market following the merger.

The big picture

Chiesi’s acquisition of KalVista strengthens its position in the rare diseases sector, particularly in hereditary angioedema (HAE) treatment. The deal underscores the strategic importance of oral, on-demand therapies in rare disease management, aligning with Chiesi’s mission to expand access to innovative treatments. The transaction also highlights the growing trend of biopharmaceutical companies consolidating to enhance their rare disease portfolios.

What we're watching

Regulatory Approvals
The pace at which EKTERLY secures additional regulatory approvals, particularly for pediatric use, will determine its market expansion potential.
Integration Challenges
How Chiesi integrates KalVista’s operations and R&D pipeline will impact the long-term success of the acquisition.
Market Competition
Whether Chiesi can sustain EKTERLY’s market position against existing and emerging HAE treatments.

Related topics

Acquisition Merger